Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bortezomib + DT204|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|DT204||DT204 is a SCF/SKP2 inhibitor that targets the ubiquitin/proteasome system, specifically inhibiting SKP1, CUL1, and COMMD1, which may result in restored sensitivity to proteasome inhibitors or overcome proteasome inhibitor resistance (PMID: 27677741).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||multiple myeloma||not applicable||Bortezomib + DT204||Preclinical - Cell line xenograft||Actionable||In a preclinical study, a Velcade (bortezomib) resistant multiple myeloma cell line overcame resistance when treatment was combined with DT204, and in xenograft models the combined treatment resulted in delayed tumor growth and improved survival (PMID: 27677741).||27677741|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|